BCRB 2018

19/09/2018

Nicotinamide

• Nicotinamide: prevents transient fluctuations in tumor blood flow that lead to development of acute hypoxia

• Hypothesis: combine nicotinamide with treatments that specifically target chronic hypoxia

33

ARCON

• A ccelerated R adiotherapy + C arb O gen + N icotinamide

Tumor cell proliferation

Chronic hypoxia

Acute hypoxia

S

S S SS S S SS D

D

D

S S

S D S S D D

D

S

S S S

S

S D D

S

D

S

S

S

S

D

S

S

S

S

S

DDDD

S S S

S S

S

S

S

S S

D

D

S

S S

S

S S S S

D S

S SS

D

S

SS D D

S

S S

D D D

D D D D S

D

S

D S

S

S S

S

S

S

D

D

S

S

D D S S

S

SS S S

D

D D

S

S

S

S

S S

D D S

D

D

S

D

S

S

S

S

S

S

D

D SS

S

DD S

S

D

S

S

S S

S

S

D

S

D

D D D D S S SS S S

D

SS

S

S

D D

D

S S

S S S

SS

D D

S S

D

SS S

S

D

S S S

S

D

D D

S S

S

D

DD S S

S DDD D S

D

SSS

Carbogen

Nicotinamide

98% O 2

+ 2% CO 2

Accelerated fractionation

S

S S SS S S SS D

D

D

S D S S D D

S S

D

S

S S S

S S

S D D

S

D

S

S

S

D

S

S

S

S

S

stem cell differentiated cell

34

S

D